PRTG News and Press, Portage Biotech Inc. From 06/22/21

Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, ...

- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to similar historical populations, balanced for prognostic factors Westport, Connecticut--...

Portage Biotech (PRTG) announced that it plans to voluntarily delist its shares from the Canadian Securities Exchange.Since its shares commenced trading on the NASDAQ in February 2021, the majority of active trading has shifted to Nasdaq.Also, it has increased operational activity at its ...

Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG" Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-onc...

Portage Biotech (PRTG) announces that the first patient has been dosed in the Phase 1 portion of the PRECIOUS-01 open-label, dose-escalation and expansion clinical trial assessing the safety, tolerability, efficacy and dosing of PORT-3 in the treatment of cancer.PORT-3 is a nanoparticle co-fo...

- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product - Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - Apr...

- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment  - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Westport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NAS...

- Out-licensing agreement facilitates focus on the Company's immuno-oncology assets - - Portage may be entitled to up to USD $244 million in future milestone payments - Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the ...

Toronto, Ontario--(Newsfile Corp. - March 2, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immune-oncology company accelerating research and development to overcome immune resistance, today announced the filing of its interim financial s...